Role of copper transporters in platinum resistance
Tóm tắt
Từ khóa
Tài liệu tham khảo
Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-861.
Wolf CR, Hayward IP, Lawrie SS, Buckton K, McIntyre MA, Adams DJ, Lewis AD, Scott AR, Smyth JF. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer 1987;39:695-702.
Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991;51:3237-3242.
Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996;88:1346-1360.
Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-4902.
Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T, Khokhar AR. Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. J Inorg Biochem 1999;77:65-70.
Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection. Cell Growth Differ 1999;10:473-478.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res 2001;11:11-19.
Holford J, Rogers P, Kelland LR. ras mutation and platinum resistance in human ovarian carcinomas in vitro. Int J Cancer 1998;77:94-100.
Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 2001;168:173-181.
Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2:35-43.
Yoshida M, Khokhar AR, Siddik ZH. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Cancer Res 1994;54:3468-3473.
Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993;67:1171-1176.
Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-3547.
Andrews PA, Velury S, Mann SC, Howell SB. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988;48:68-73.
Eichholtz-Wirth H, Hietel B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br J Cancer 1986;54:239-243.
Shellard SA, Fichtinger-Schepman AM, Lazo JS, Hill BT. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 1993;4:491-500.
Vermorken JB, van der Vijgh WJ, Klein I, Hart AA, Gall HE, Pinedo HM. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 1984;68:505-513.
Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 1992;52:149-153.
Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, Loo TL. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 1982;10:51-54.
Pujol JL, Cupissol D, Gestin-Boyer C, Bres J, Serrou B, Michel FB. Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients. Cancer Chemother Pharmacol 1990;27:72-75.
Guancial EA, Kilari D, Messing EM, Kim ES. Platinum concentration in bladder tissue treated with neoadjuvant chemotherapy and pathologic responsee. ASCO Meeting Abstracts, 2015; 33: 341. Available from: <ext-link ext-link-type="uri" xlink:href="http://meeting.ascopubs.org/cgi/content/abstract/33/7_suppl/341" xmlns:xlink="http://www.w3.org/1999/xlink">http://meeting.ascopubs.org/cgi/content/abstract/33/7_suppl/341</ext-link>.
Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O’Halloran TV. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 1999;284:805-808.
Yoshizawa K, Nozaki S, Kitahara H, Ohara T, Kato K, Kawashiri S, Yamamoto E. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines. Oncol Rep 2007;18:987-991.
Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000;60:1312-1316.
Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002;62:6559-6565.
Zhou B, Gitschier J. hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci USA 1997;94:7481-7486.
Kim H, Son HY, Bailey SM, Lee J. Deletion of hepatic Ctr1 reveals its function in copper acquisition and compensatory mechanisms for copper homeostasis. Am J Physiol Gastrointest Liver Physiol 2009;296:G356-G364.
Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004;3:1543-1549.
Ogane N, Yasuda M, Kameda Y, Yokose T, Kato H, Itoh A, Nishino S, Hashimoto Y, Kamoshida S. Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin. Biomed Res 2013;34:143-151.
Kilari D, Iczkowski K, Robin A, Pandya C, Bylow KA, Langenstroer P, Messing EM, Guancial EA, Kim ES. Association between copper transporter receptor 1(ctr1) expression and pathologic outcomes in cisplatin (pt)-treated bladder cancer (bc) patients. ASCO Meeting Abstracts 2014; 32: e15516. Available from: <ext-link ext-link-type="uri" xlink:href="http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15516" xmlns:xlink="http://www.w3.org/1999/xlink">http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15516</ext-link>.
Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson’s disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51:545-554.
Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 1981;14:189-207.
MIlls CF, El-Gallad TT, Bremner I, Weham G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 1981;14:163-175.